+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

From
HPV Associated Disorders Market Report 2025 - Product Thumbnail Image

HPV Associated Disorders Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Advanced Cervical Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Cervical Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 160 Pages
  • Global
From
Bispecific antibody - Competitive landscape, 2023 - Product Thumbnail Image

Bispecific antibody - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
Collaboration Deals in Pharmaceuticals 2019-2025 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2025

  • Report
  • April 2025
  • 950 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2025 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2019-2025

  • Report
  • April 2025
  • 1400 Pages
  • Global
From
From
Ovarian Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Ovarian Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Fallopian Tube Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Fallopian Tube Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
From
From
Arzerra - Product Thumbnail Image

Arzerra

  • Report
  • January 2019
  • 18 Pages
  • Global
From
From
Loading Indicator